Dr. Sudip Vhaduri is an assistant professor in the Department of Computer and Information Science at Fordham University. He received Ph.D. in Computer Science & Engineering from the University of Notre Dame in 2019. Over the past eight years, Dr. Vhaduri has worked in diverse and interdisciplinary research teams at various renowned institutions, such as IBM Research, from different parts of the globe. His research integrates artificial intelligence and mobile crowdsensing & computing in various application areas, including mobile health. Dr. Vhaduri and his interdisciplinary teams are developing smartphone- and wearable-based low-cost, wide-scale adaptable, and sustainable socio-economic healthcare solutions to empower people towards better management of health behaviors and foster better communication between healthcare providers and patients to reduce healthcare burdens.
40+ yrs. of experience commercializing MedTech/pharma Co-founder of 4 companies with successful Chairman and CEO of Other Pharmaceuticals (2003-2010), a specialty pharmaceutical company focused on treatments for ophthalmic diseases Co-founder, President, CEO and Chairman of Orthovita (1999-2008), an Orth biologic company (IPO in 2006; acquired by Stryker (NYSE:SYK) in 2012 for US$350 million) Co-founder, President, CEO and Chairman of Surgical Laser Technologies (IPO in 1989. acquired by Photo Medix in 1992) Co-founder, President, CEO and Chairman of SITE Microsurgical acquired by J&J
Parimala Rao BS, MT (ASCP), CIC is the Point of Care Assistant at Einstein Medical Center located in the suburbs of Philadelphia, PA. Prior to her current role, Parimala served as a Medical Technologist and an Infection Preventionist , in which the core of her efforts focused on hospital acquired infection surveillance, outbreak investigation, communicable disease exposure prevention, and emergency preparedness. She has a strong background focused on medical laboratory sciences, microbiology, and epidemiology. Additionally, she has excellent communication skills with doctors, nurses, and other healthcare professionals in providing quality patient care, stays abreast with new test procedures and methodologies. Parimala, while not assisting in patient care, loves to travel around the world with her husband and two teenage daughters. Also enjoys spending time with her husband in real estate business and is very active in the community events.
Dr. Abelardo -Currently, as Lab Supervisor for Point of Care Testing at Mount Sinai Hospital of Queens, Abelardo monitors quality assurance and validates POC instruments such as GEM 5000 blood gas analyzers, glucometers, Clinitek Status+ analyzers, LIAT analyzers, and Hemochron Signature Elite instruments. He coordinates with Nurse Educators for implementation of in-service for incoming RNs, MDs and Medical Assistants for POC instruments. In addition, with the help of Point of Care Coordinator, performs certification and recertification of qualified operators – MDs, RNs and MAs for both hospital and clinics.
Marcos Amato is the Managing Director of Agdia EMEA, the subsidiary of Agdia Inc. based in France and in charge of Europe, Africa and Middle East markets. Marcos was born in Argentina and raised in Italy. He obtained his Ph.D in developmental molecular biology from Paris-Sud University in 2005 and a Master in International Business in 2006 . He joined Agdia EMEA as sales representative and has been working for more than a decade on the agricultural market. Marcos has travelled to over 25 countries, providing rapid diagnostic solutions for plant pathogen in all agricultural sectors. Marcos lives in Paris area with wife and two children. He enjoys reading, spending time with family and friends and meeting people from all over the world.
Coilin Walsh is the Director of Marketing & Quality Manager at Agdia, Inc. Coilin has been involved in serological and molecular diagnostics since the early 2000’s. He spent the earlier part of his career developing rapid commercial diagnostic assays for antibiotic residues & mycotoxins in food products in addition to tests for plant pathogens & GMOs in the agricultural industry. He has been involved in the successful implementation of ISO certifications & accreditations of quality management systems (QMS). He has also held leadership positions in various groups including the American Chemical Society (ACS). Coilin enjoys the outdoors and spending time with his wife and children on their 5-acre homestead.
Bob has over 20 years of experience in the healthcare industry. He started his career in the NHS as a Haematology and Transfusion Biomedical Scientist and subsequently held leadership roles across commercial, product and implementation functions within Bayer Diagnostics, Siemens, and Abbott Point of Care. He is passionate about innovative Medical technology and specializes in the Commercialization of haematology products. He is a believer in transforming science to revenue and has supported a number or early-stage and mature companies in their commercial plans as an independent consultant. As Sight Diagnostics' VP Sales International, he is responsible for Sight's commercial strategy and execution for direct and indirect markets outside of the United States.
|
Diana is a Point of Care Coordinator (POC) and oversees POC Testing at Mount Sinai Health System’s Hospital in Queens (MSQ), New York. Some of the instruments that Diana validates and teaches nurses and medical providers on proper usage and resulting by providing certification to corresponding instruments, entail Glucometer, Clinitek Status+, Hemochron Elite, i-STAT, GEM 5000, Cholestech LDX, and LIAT. Diana also coordinates biannual health fair for MSQ as a representative from the laboratory. She is certified as a medical laboratory technologist by American Society for Clinical Pathology |
Alan H.B. Wu, Ph.D., DABACC, is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospital Professor of Laboratory Medicine, University of California, San Francisco, and medical director for the Pharmacogenomics Laboratory. He received B.S. degrees in chemistry and biology at Purdue University, West Lafayette, Indiana, and a Ph.D. degree in analytical chemistry at the University of Illinois, Champaign-Urbana, Illinois. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry. His research interests include pharmacogenomics, clinical toxicology, cardiac biomarkers, and point-of-care testing. Dr. Wu has over 400 publications in peer-reviewed journals. He has also written five paperback books consisting of short stories designed to promote the value of the clinical laboratory and pharmacogenomics to the general public.
Mohamed Abdalla has spent his life using his personal and career experiences to participate making the Point of care more interesting to the health care providers. While his focus is on Point of care, he also has experience in other parts of the lab. He knows there is no single approach that works for everyone, so he continues to educate himself on new teaching methodologies and explore the market for the new POCT devices that work for each of unit needs. He received his education at the Alribat National University in Sudan with a BSC Degree in Clinical laboratory. He was the first in his class in the first year second semester. Mohamed is currently in tertiary Government Hospital in Riyadh-Kingdom of Saudi Arabia where he lives with his wife and one young boy.
Guo was graduated in Pharmaceutical Faculty of Shandong University in 1982 and completed his advanced study at Institute of Clinical Pharmacology, Bern University of Switzerland from May. 1991 to Sept. 1993. He is an Editorial board members of Chinese J of Clinical Pharmacology and Therapeutics, Chinese J of Hospital Pharmacy, Pharmaceutical Care and Research, Chinese J of Clinical Pharmacy, J of Shandong University (health science, as Associate Chairmen of TDM of Chinese Pharmacology Society, Standing Committee members of Clinical Pharmacy of Chinese Medical Society, as Chairmen of Hospital Pharmacy of Shandong Pharmaceutical Society, Chairmen of TDM of Shandong Pharmaceutical Society, and so on.
Dr Pedro Estrela is the Director of the Centre for Biosensors, Bioelectronics and Biodevices (C3Bio) and an Associate Professor in the Department of Electronic & Electrical Engineering at the University of Bath. He has 20 years research experience in biosensors. His research focuses on the development of label-free electrical, electrochemical and plasmonic biosensors for a wide range of applications such as medical diagnostics and environmental monitoring; microfluidic sample processing; biodevice integration. He is member of the Executive Team of the Centre for Therapeutic Innovation, Theme Leader (Healthcare Technologies) at the Centre for Sustainable Circular Technologies, Theme Leader (Sensors & Data) at the Water Innovation & Research Centre. He has over 130 publications (Scopus h-index 27) and is Associate Editor for the journals Biosensors & Bioelectronics, Scientific Reports, Sensors, Bio Nanoscience and Frontiers in Sensors.
Jyoti Chandok is a seasoned professional who has been working in the healthcare sector for over 19 years. She has fulfilled several roles specializing in patient care including phlebotomy, blood analysis for hematology, immunology, genetics, and specialized method development for HIV drug-level testing using mass spectrometry. Currently, Jyoti is an Assistant Chief Medical Technologist of Point-of-Care at the McGill University Health Center (MUHC) in Montreal, Quebec, Canada. She holds a B.Sc. in Cell and Molecular Biology from Concordia University and is an active member of both the Ordre professionnel des technologistes médicaux du Québec (OPTMQ) and the Canadian Society for Medical Laboratory Science (CSMLS).
Dr. Kevin Wang is the Director of the Program for Neurotrauma, Neuroproteomics and Biomarkers Research and Professor of Emergency Medicine, Neuroscience, Physiological Sciences and Chemistry at the University of Florida in USA. He is also Research Health Neuroscientist, and Executive Committee Member of the Brain Rehabilitation Research Center, Malcom Randall VA Medical Center (Gainesville, FL). Dr. Wang is a neurotrauma researcher since the late 1990’s. He has served as President and Council Member of the National Neurotrauma society, Board Member, Board of Governors of the International Brain Injury Association and Presidium Member of the Academy for Multidisciplinary Neurotraumatology. He is a co-founder of a biotechnology company Gryphon Bio, Inc. His research focus is translational research for biomarkers and therapies for traumatic brain injury (TBI), spinal cord injury, post-traumatic epilepsy, and chronic traumatic encephalopathy. Two acute TBI blood-based protein biomarkers (UCH-L1/GFAP) he co-discovered have received FDA clearance as the first in vitro diagnostic tests for detecting pathoanatomical lesions in TBI patients. He also holds leadership positions on various TBI initiatives such as International TBI Research Initiative (InTBIR), and multicenter TBI consortium studies (e.g. TRACK-TBI, CENTER-TBI, ICON-TBI). Dr. Wang is principle Investigator of multiple research grants funded by National Institute of Health, Department of Defense, Veterans Affairs and other research foundations. He has also authored over 300 peer-reviewed publications and edited /co-edited 5 scientific books.
